NYSE$HCA

HCA Holdings Inc · Q1 2020 earnings

Q1 2020 earnings · · Investor relations

Briefing

HCA Healthcare's financial performance declined in Q1 2020 due to COVID-19 impact and losses on debt retirement.

HCA Healthcare's Q1 2020 results were impacted by the COVID-19 pandemic, leading to a decrease in net income despite a slight increase in revenues. The company has withdrawn its 2020 guidance due to uncertainty related to the pandemic.

  • Revenues increased to $12.861 billion compared to $12.517 billion in Q1 2019.
  • Net income attributable to HCA Healthcare, Inc. decreased to $581 million, or $1.69 per diluted share, from $1.039 billion, or $2.97 per diluted share, in Q1 2019.
  • Adjusted EBITDA totaled $2.200 billion, down from $2.541 billion in Q1 2019.
  • The company withdrew its previously issued guidance for 2020 due to the uncertainty caused by COVID-19.

Headline financials

Total Revenue

$12.9B

Previous: $12.5B+2.7%
EPS (adj)

$2.33

Previous: $2.78-16.2%
Admissions

528.2K

Previous: 523.2K+1.0%
Number of Hospitals

186

Previous: 185+0.5%
Licensed Beds at End of Period

49.4K

Previous: 48.5K+1.9%
Occupancy

58.6%

Previous: 60.3%-2.8%
Average Length of Stay (days)

4.965

Previous: 4.983-0.4%
Capital Expenditures

-$853M

Previous: -$781M-9.2%
Free Cash Flow

-$272M

Previous: $258M-205.4%
Net Income

$581M

Previous: $1.04B-44.1%
Operating Income

-$2.52B

Previous: -$2.4B-4.8%
Gross Profit

$10.7B

Previous: $10.5B+2.5%
Cash & Equivalents

$731M

Previous: $531M+37.7%
Total Assets

$45.4B

Previous: $43.4B+4.7%
Stock-Based Comp

$82M

Previous: $62M+32.3%

Revenue & EPS history

HCA · Revenue · Quarterly

$12.9B

Q1 2020+2.7%vs Q1 2019
Beat estimate in 10 of 16 quarters(63%)
ActualEstimate

Forward guidance

Due to the uncertainty related to the COVID-19 pandemic, HCA Healthcare has withdrawn its previously issued guidance for 2020.

Tailwinds

  • Implemented certain cost reduction initiatives
  • Suspended its authorized share repurchase program
  • Reduced certain planned capital expenditures
  • Executed a new $2 billion 364-day term loan facility (which was undrawn at March 31, 2020) to supplement revolver availability
  • Requested accelerated Medicare payments as provided for in the Coronavirus Aid, Relief, and Economic Security (CARES) Act subsequent to March 31, 2020

Headwinds

  • The extent of COVID-19’s adverse impact on its operating results and financial condition will be driven by many factors, most of which are beyond the Company’s control and ability to forecast.
  • Changes in revenues due to declining patient volumes, changes in payor mix and deteriorating macroeconomic conditions
  • Potential increased expenses related to labor, supply chain or other expenditures
  • Workforce disruptions and supply shortages and disruptions
  • Suspended its quarterly dividend program

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2020

Historical avgQ1 2020

-0.1%

Avg return

Earnings day

+0.8%

Avg return

5 days after

+2.9%

Avg return

30 days after

47%

31 / 66 earnings

Positive

+16.1%

Q2 2020

Best reaction

-21.9%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-5.2%-8.3%-16.8%
Q4 2025+6.2%+3.4%+11.3%
Q3 2025+1.5%+6.4%+11.6%
Q2 2025+0.8%+3.1%+3.8%
Q1 2025-4.0%+1.1%+10.3%
Q4 2024-3.8%+0.7%-2.7%
Q3 2024-10.6%-9.5%-18.5%
Q2 2024+5.7%+9.0%+17.7%
Q1 2024-0.9%-1.5%+1.5%
Q4 2023+6.3%+7.9%+8.7%
Q3 2023-6.5%-6.5%+5.0%
Q2 2023-3.2%-2.9%-3.2%
Q1 2023+5.7%+2.7%+4.3%
Q4 2022-0.6%+2.6%-2.2%
Q3 2022+0.8%+4.3%+10.3%
Q2 2022+9.6%+12.9%+18.6%
Q1 2022-21.9%-21.2%-24.0%
Q4 2021-1.4%-1.1%+5.5%
Q3 2021-7.0%-5.6%-8.1%
Q2 2021+14.5%+14.2%+13.3%
Q1 2021+2.5%+0.7%+4.5%
Q4 2020+3.7%+5.9%+5.6%
Q3 2020-4.4%-9.3%+12.5%
Q2 2020+16.1%+14.6%+21.2%
Q1 2020-5.4%-2.4%-2.2%
Q4 2019+2.6%-2.0%-10.1%
Q3 2019+6.2%+5.3%+10.3%
Q2 2019-8.7%-13.0%-17.4%
Q1 2019-1.1%+0.2%-2.3%
Q4 2018+5.6%+6.1%+5.5%
Q3 2018+3.5%+4.2%+12.0%
Q2 2018+14.9%+14.7%+21.4%
Q1 2018+2.1%+1.9%+7.7%
Q4 2017+3.6%+2.1%+1.9%
Q3 2017+0.9%+0.3%+11.6%
Q2 2017-5.2%-6.6%-7.9%
Q1 2017-1.2%-0.4%-0.1%
Q4 2016+3.4%+5.7%+10.2%
Q3 2016-2.1%-4.5%-9.6%
Q2 2016-1.1%-3.8%-4.8%
Q1 2016-1.7%
Q4 2015+3.1%
Q3 2015-0.1%
Q2 2015-2.8%
Q1 2015-1.2%
Q4 2014-1.7%
Q3 2014-2.1%
Q2 2014+4.1%
Q1 2014-1.2%
Q4 2013-1.0%
Q3 2013-5.1%
Q2 2013+0.1%
Q1 2013+3.8%
Q4 2012-1.1%
Q3 2012+8.0%
Q2 2012+1.1%
Q1 2012-1.1%
Q4 2009+3.5%
Q4 2011+3.5%
Q3 2011+2.6%
Q3 2010+2.6%
Q2 2011-20.6%
Q2 2010-20.6%
Q1 2011-0.2%
Q1 2010-0.2%
Q4 2010-0.2%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro